Clinical trials: Clinical Research
Prostate Cancer Metastatic
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
- Trial name
- NCT02407054
- Testing
- LY3023414, Enzalutamide
- Where
- 36 sites in United States
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Neoplasm Malignant, Breast Cancer
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Primary Objectives: Part 1 (Dose Escalation) To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for…
- Conditions
- Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer
- Trial name
- NCT05013554
- Testing
- SAR443216 IV, SAR443216 SC
- Where
- 11 sites in United States, Belgium and 4 more
- Volunteers
- 44 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
- Trial name
- NCT04641754
- Testing
- WX-0593 Tablets
- Where
- 41 sites in China
- Volunteers
- 176 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
Study E2730-A001-001 is a first-in-human, sequential ascending single dose, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of E2730 in healthy participants.
- Trial name
- NCT03054194
- Testing
- E2730
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Atopic Dermatitis
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07643766
- Testing
- ENV-294
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Enveda Therapeutics
Neoplasms
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
This study will evaluate the pharmacokinetics, maximum tolerated dose and anti-tumor activity of RO5083945 in patients with metastatic and/or locally advanced malignant EGFR+ solid tumors.
- Trial name
- NCT00721266
- Testing
- RO5083945
- Where
- 5 sites in France, Spain
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
HIV-1
A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
This is a study to assess long-term safety and efficacy of lersivirine in patients who have completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.
- Trial name
- NCT01254656
- Testing
- lersivirine, efavirenz, etravirine
- Where
- 23 sites in Australia, Brazil and 7 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Gastric Outlet Obstruction
Clinical Trial of EPASS With Hot AXIOS System
A prospective, multi-center, single-arm study for unresectable malignant gastric outlet obstruction with EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS)
- Trial name
- PASSAGE (NCT05644951)
- Testing
- Hot AXIOS system used for EPASS
- Where
- 6 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Patients With Mild or Moderate Hepatic Impairment
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment
- Trial name
- NCT07231029
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Infertility
Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment
The purpose of this study is to record and evaluate the use of traditional morphology grading combined with Eeva in the treatment of in vitro fertilization.
- Trial name
- MERGE (NCT01816802)
- Testing
- In-vitro fertilization using Eeva
- Where
- 12 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Progyny, Inc.
Covid19
A Phase III Confirmatory Study of K-237
The efficacy and safety of K-237 0.3-0.4 mg/kg orally administered once daily for 3 days will be evaluated in patients with mild COVID-19 using a randomized, double-blind, parallel-group comparative method with placebo as a…
- Trial name
- NCT05056883
- Testing
- K-237 0.3-0.4mg/kg (once daily)
- Where
- 55 sites in Japan, Thailand
- Volunteers
- 1,030 people
- Sponsor
- Kowa Company, Ltd.
Osteoarthritis, Hip
MONOVISC for Hip Joint Pain Relief Due to Osteoarthritis
Obtain real world, post market data to confirm the clinical improvement and safety in patients treated with a single injection of MONOVISC for the symptomatic relief of osteoarthritis in the hip joint.
- Trial name
- NCT04204083
- Testing
- Monovisc
- Where
- 4 sites in Czechia, Poland
- Volunteers
- 25 people
- Sponsor
- Anika Therapeutics, Inc.
Typhoid Fever
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.
- Trial name
- NCT00498654
- Testing
- Ty800 (Salmonella typhi) Oral Vaccine
- Where
- 5 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Avant Immunotherapeutics
Obstructive Sleep Apnea
A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
This study is conducted to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea
- Trial name
- NCT03765294
- Testing
- ACT-541468
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy Volunteers
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
- Trial name
- NCT00788294
- Testing
- tanezumab
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer
Blood Disease, Blood Transfusion, Autologous
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.
- Conditions
- Blood Disease, Blood Transfusion, Autologous, Blood Doping, Blood Transfusion, Homologous
- Trial name
- Transfusion (NCT03548766)
- Testing
- Homologous Blood Transfusion, Autologous Blood Transfusion
- Where
- Qatar
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Healthy Volunteer, Type 2 Diabetes
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes…
- Trial name
- NCT02164266
- Testing
- RO6799477
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.